{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:32:04Z","timestamp":1794310324818,"version":"4.9.0"},"reference-count":42,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Cefazolin (CFZ) is the first-line treatment for beta-lactamase-producing methicillin-sensitive Staphylococcus aureus (BP-MSSA) infection. In 2019, Japan experienced a CFZ shortage because of foreign object inclusion in a batch. Ampicillin\/sulbactam (SAM) was preferred in many cases as definitive therapy for the treatment of BP-MSSA bacteremia to preserve broad-spectrum antibiotic stock. However, there are no previous studies reporting the clinical efficacy of SAM for BP-MSSA bacteremia. We aimed to compare the clinical efficacy and adverse effects of SAM versus CFZ in patients with BP-MSSA bacteremia. In total, 41 and 30 patients treated with SAM and CFZ, respectively, were identified. The baseline characteristics were similar in both groups. No significant differences were observed in length of hospital stay and all 30-day mortality between the two groups (p = 0.270 and 0.643, respectively). Moreover, no intergroup difference in 90-day mortality was found (hazard ratio 1.02, 95% confidential interval 0.227\u20134.53). Adverse effects, such as liver dysfunction, were less in the CFZ group than in the SAM group (p = 0.030). Therefore, in cases of poor CFZ supply or in patients allergic to CFZ and penicillinase-stable penicillins, SAM can be an effective therapeutic option for bacteremia due to BP-MSSA with attention of adverse effects, such as liver dysfunction.<\/jats:p>","DOI":"10.3390\/antibiotics11111505","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T23:45:00Z","timestamp":1667087100000},"page":"1505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Effectiveness of Ampicillin\/Sulbactam versus Cefazolin as Targeted Therapy for Bacteremia Caused by Beta-Lactamase-Producing Methicillin-Sensitive Staphylococcus aureus: A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-7175","authenticated-orcid":false,"given":"Jun","family":"Hirai","sequence":"first","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute 480-1103, Japan"},{"name":"Department of Infection Control and Prevention, Aichi Medical University Hospital, Nagakute 480-1103, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute 480-1103, Japan"},{"name":"Department of Infection Control and Prevention, Aichi Medical University Hospital, Nagakute 480-1103, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University, Nagakute 480-1103, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Kishino","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Aichi Medical University Hospital, Nagakute 480-1103, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-9560","authenticated-orcid":false,"given":"Hideo","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sakanashi","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Aichi Medical University Hospital, Nagakute 480-1103, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Clinical Research Center, Aichi Medical University, Nagakute 480-1103, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute 480-1103, Japan"},{"name":"Department of Infection Control and Prevention, Aichi Medical University Hospital, Nagakute 480-1103, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: Results from a large multicentre cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_2","first-page":"341","article-title":"Staphylococcus aureus bacteremia: Contemporary management","volume":"117","author":"Abraham","year":"2020","journal-title":"Mo Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jcpt.12743","article-title":"Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Lewis","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","article-title":"Staphylococcus aureus infections","volume":"339","author":"Lowy","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.1892","article-title":"\u03b2-Lactam therapy for methicillin-susceptible Staphylococcus aureus bacteremia: A comparative review of cefazolin versus antistaphylococcal penicillins","volume":"37","author":"Li","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00485-11","article-title":"Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjms.2020.04.006","article-title":"Comparison of nafcillin and cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia","volume":"360","author":"Twilla","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: A prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Koizumi, R., Kusama, Y., Asai, Y., Yoshiaki, G., Muraki, Y., and Ohmagari, N. (2021). Effects of the cefazolin shortage on the sales, cost, and appropriate use of other antimicrobials. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-07139-z"},{"key":"ref_11","unstructured":"Nichi-iko (2021, September 02). Cefazolin Sodium Details of Supply Issue. (In Japanese)."},{"key":"ref_12","unstructured":"Ministry of Health, LaW (2022, September 02). Alternative Drug List for Cefazolin Shortage, (In Japanese)."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofy089","DOI":"10.1093\/ofid\/ofy089","article-title":"A Comparison of cefazolin versus ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia in a tertiary care VA medical center","volume":"5","author":"Carr","year":"2018","journal-title":"Open Forum. Infect Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","article-title":"Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia","volume":"15","author":"Wong","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus Bacteremia","volume":"25","author":"Jensen","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"ofy068","DOI":"10.1093\/ofid\/ofy068","article-title":"Antimicrobial agent shortages: The new norm for infectious diseases physicians","volume":"5","author":"Gundlapalli","year":"2018","journal-title":"Open Forum. Infect Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Uda, A., Shigemura, K., Kitagawa, K., Osawa, K., Onuma, K., Yan, Y., Nishioka, T., Fujisawa, M., Yano, I., and Miyara, T. (2021). Risk factors for the acquisition of enterococcus faecium infection and mortality in patients with enterococcal bacteremia: A 5-year retrospective analysis in a tertiary care university hospital. Antibiotics, 10.","DOI":"10.3390\/antibiotics10010064"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Uda, A., Onuma, K., Shigemura, K., Kitagawa, K., Yan, Y., Osawa, K., Yano, I., and Miyara, T. (2021). Impact of cefazolin shortage on clinical outcomes of adult patients with bacteremia caused by methicillin-susceptible Staphylococcus aureus in a tertiary care university hospital. Antibiotics, 10.","DOI":"10.3390\/antibiotics10101247"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","unstructured":"Peechakara, B.V., and Gupta, M. (2022, October 19). Ampicillin\/Sulbactam, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526117\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/clinids\/11.3.361","article-title":"Inoculum effect","volume":"11","author":"Brook","year":"1989","journal-title":"Rev. Infect Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jiac.2013.09.008","article-title":"Cefazolin therapy for methicillin-susceptible Staphylococcus aureus bacteremia in Japan","volume":"20","author":"Shoji","year":"2014","journal-title":"J. Infect. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/379021","article-title":"Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: Revisiting the issue","volume":"37","author":"Nannini","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/mdr.2013.0229","article-title":"Clinical implications of cefazolin inoculum effect and \u03b2-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia","volume":"20","author":"Lee","year":"2014","journal-title":"Microb. Drug. Resist."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10096-016-2799-1","article-title":"Characteristics of cefazolin inoculum effect-positive methicillin-susceptible Staphylococcus aureus infection in a multicentre bacteraemia cohort","volume":"36","author":"Song","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jiac.2017.10.021","article-title":"Inoculum effect of high concentrations of methicillin-susceptible Staphylococcus aureus on the efficacy of cefazolin and other beta-lactams","volume":"24","author":"Saeki","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"ofy123","DOI":"10.1093\/ofid\/ofy123","article-title":"The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"5","author":"Miller","year":"2018","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_31","unstructured":"US Food and Drug Administration (2021, September 02). Drug Shortages: Root Causes and Potential Solutions, Available online: https:\/\/www.fda.gov\/media\/131130\/download."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M17-2820","article-title":"Prognostic accuracy of the quick sequential organ failure assessment for mortality in patients with suspected infection: A systematic review and meta-analysis","volume":"168","author":"Fernando","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Minejima, E., Delayo, V., Lou, M., Ny, P., Nieberg, P., She, R.C., and Wong-Beringer, A. (2019). Utility of qSOFA score in identifying patients at risk for poor outcome in Staphylococcus aureus bacteremia. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3770-4"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jama.2016.0288","article-title":"Assessment of clinical criteria for sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Seymour","year":"2016","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit. Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1164\/rccm.201611-2262OC","article-title":"New sepsis definition (Sepsis-3) and community-acquired pneumonia mortality: A validation and clinical decision-making study","volume":"196","author":"Ranzani","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1017\/S0950268818002480","article-title":"The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia","volume":"146","author":"Ragozzino","year":"2018","journal-title":"Epidemiol. Infect."},{"key":"ref_41","unstructured":"CLSI (2015). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement, Clinical and Laboratory Standards Institute. CLSI Document M100-S25."},{"key":"ref_42","unstructured":"CLSI (2015). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, Clinical and Laboratory Standards Institute. [10th ed.]. CLSI Document M7-A10."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/11\/1505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:20Z","timestamp":1760144720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/11\/1505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["antibiotics11111505"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11111505","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}